Top Biotech & Pharma Journalists | Notified
15 Popular Journalists Covering Biotech and Pharma
Meet the reporters shaping today’s biotech and pharma news - from drug discovery to FDA decisions and the future of healthcare.
December 8, 2025
15 Popular Journalists Covering Biotech and Pharma
Biotech and pharma moves quickly, and the journalists who cover this world help make sense of science, strategy and decisions shaping the future of healthcare.
From drug approvals and clinical trials to policy decisions, research milestones and the business of life sciences, these 15 reporters bring clear, thoughtful reporting to the most important stories in the industry.
If you work in PR or communications for a life sciences company, these are the names worth following.
1. Jonathan Rockoff – Health Business Editor, The Wall Street Journal
Jonathan Rockoff covers biotech and pharmaceutical markets for The Wall Street Journal, bringing deep insight into drug-pricing strategies, biotech M&A and how policymakers influence healthcare innovation. His reporting often uncovers the tension between corporate ambitions and public policy, whether it's a pharma giant striking deals or navigating regulatory pressures.
Rockoff’s stories help readers understand the business of medicine, not just science. He breaks down complex pharma deals and pricing strategies into clear narratives, showing how corporate decisions ripple into health policy, patient access, and global market dynamics.
Recent Articles by Jonathan Rockoff:
- Pfizer and Metsera Reach Deal Expected to Top $10 Billion
- Pfizer Preps Improved Offer in Metsera Bidding War
- Inside Pfizer’s Drug-Pricing Deal With the Trump Administration
2. Elaine Chen – National Biotech Reporter, STAT News
Elaine Chen at STAT News dives into biotech and pharma, showing how big scientific ideas meet corporate strategy and regulation. She's great at breaking down complex stories, making the "why it matters" clear for everyone from investors to doctors.
Recent Articles by Elaine Chen:
- “Why is Eli Lilly worth nearly $1 trillion?”
- “Chinese government’s support for biotech fuels huge rally”
- “The $10 billion question: Will Pfizer hit it big with Metsera, or have regrets?”
3. Katherine Davis – Biotech Deals Reporter, Axios
Katherine Davis at Axios Pro Deals is the go-to reporter for the money side of biotech. She breaks down complex venture capital, M&A and private equity deals to show investors and founders what these financial moves really mean for drug development and long-term company strategy.
Recent Articles by Katherine Davis:
- Sofinnova Partners closes €650M fund
- Merck to buy Cidara Therapeutics in $9.2B deal
- The GLP-1 gold rush is just beginning
4. Ahmed Aboulenein – U.S. Health & Pharma Policy Reporter, Reuters
Ahmed Aboulenein covers U.S. health policy, pharmaceutical regulation, and federal agency decision-making for Reuters. His reporting often sits at the intersection of politics, science and public health, especially when new policies or regulatory shifts have sweeping implications for drugmakers, clinicians and patients.
Recent Articles by Ahmed Aboulenein:
- U.S. FDA plans to tap oncology expert Pazdur as top drug regulator
- FDA chief urges drugmakers to remove old warnings from hormone-therapy meds
- Trump’s surgeon-general nominee Casey Means faces Senate grilling
5. Lisa Schencker – Health Care Reporter, Chicago Tribune
Lisa Schencker covers hospitals and health policy for the Chicago Tribune. She focuses on how changes in laws and hospital decisions actually affect patients and families in Illinois, making complex health debates feel real.
Recent Articles by Lisa Schencker:
- Millions could lose access to subsidized ACA plans if Obamacare changes move forward
- Illinois hospitals see shifts in safety grades as new Leapfrog ratings come out
- Hospitals pull back gender-affirming care for minors under Trump policies
6. Rebecca Robbins – Health & Pharma Reporter, The New York Times
Rebecca Robbins reports on medicine, drug pricing, and policy at The New York Times. She shines a light on how regulatory decisions, pricing deals, and market forces shape access to treatments and affect public health.
Recent Articles by Rebecca Robbins:
- “R.F.K. Jr. and Drugmakers Clash Over Obesity-Drug Access”
- “FDA Names Richard Pazdur Its Top Drug Regulator”
- “F.D.A. Moves to Speed Approvals for Cheaper Copycat Drugs”
7. Joseph Choi – Health Care Reporter, The Hill
Joseph Choi covers health care policy, regulatory developments and industry-politics intersections at The Hill. His reporting zeroes in on how legislative choices and agency decisions shape access to care and the broader pharma ecosystem.
Recent Articles by Joseph Choi:
- “Vaccination rates decline across America, raising concerns among health experts”
- “Senate Republicans unsure of next steps on health-care reforms”
- “FDA drops hormone-therapy black-box warning, marking regulatory shift”
8. Maggie Fick – Global Pharmaceuticals Correspondent, Reuters
Maggie Fick at Reuters tracks the global business of pharmaceuticals, concentrating on major M&A, obesity drugs and how the world's biggest drug companies handle political and market pressures. Her reports are vital because they combine clear financial analysis with strong industry context.
Recent Articles by Maggie Fick:
- “Novo Nordisk faces rare shareholder rebuke over board shake-up”
- “Novo Nordisk CEO signals new appetite for risk in obesity-drug deals”
- “Pfizer sweetens offer in Metsera bidding war against Novo”
9. Hannah Kuchler – Global Pharmaceutical Editor, Financial Times
Hannah Kuchler leads coverage on the global pharma industry for the Financial Times, tracking big-picture trends in drug-pricing, innovation and competition. Her reporting often spotlights how major drugmakers strategize around obesity, M&A and regulatory risk.
Recent Articles by Hannah Kuchler:
- “‘Not desperate’: Novo Nordisk’s new boss defends strategy”
- “Novo Nordisk challenges Pfizer to raise offer for obesity biotech”
- “Roche agrees biggest-ever obesity drug deal”
10. Anna Brown – Reporter, Endpoints News
Anna Brown covers biotech, pharma manufacturing, CDMOs, and regulatory updates for Endpoints News. Her reporting is practical, fast-moving and often centers on how industry decisions impact operations, supply chains and commercial strategy.
Recent Articles by Anna Brown:
- “Catalent lays off more gene therapy workers in Baltimore”
- “As pharma pour billions in US manufacturing, CDMOs see future opportunities”
- “Abeona’s skin disease cell therapy launch stymied by false-positive sterility test”
11. Helena Beer – Editor & Reporter, Hospital Pharmacy Europe
Helena Beer focuses on clinical pharmacy, medicines safety, emerging research and the evolving role of hospital pharmacists. Her articles often break down complex science into clear, practical takeaways for healthcare professionals.
Recent Articles by Helena Beer:
- “AI could save healthcare staff 43 minutes admin time per day, pilot suggests”
- “PK-PD modelling in predicting small molecule drug toxicities”
- “Maximising hospital pharmacy: translating research into paediatric patient care”
12. David Wild – Senior Writer, Citeline / In Vivo
David Wild covers the people, ideas and technologies shaping the future of biopharma. His reporting often blends executive insight, scientific innovation and the business decisions that move the industry forward.
Recent Articles by David Wild:
- “Cellprothera targeting heart regeneration where no treatment exists”
- “A $30m milestone and leadership handoff signal new chapter for Recursion”
- “How rare disease advocates are reshaping gene therapy development”
13. Paul Naphtali – Senior Science Writer, BioCompare
Paul Naphtali writes for BioCompare, covering molecular biology techniques, biomarker development and the tools that underpin drug discovery. His articles make highly technical science more accessible and relevant to both researchers and the broader biotech community.
Recent Articles by Paul Naphtali:
- “Sample Processing for Nucleic Acid Analyses”
- “Developing Novel Biomarkers with Liquid Biopsy”
- “Predictive Markers for Drug Responses”
14. Annalee Armstrong – Senior Editor, BioSpace
Armstrong covers the major biopharma storylines, including bidding wars, FDA decisions and executive changes. Her reporting combines sharp analysis with a look at the industry's human side, making complex topics like deals and policy shifts easy to understand.
Recent Articles by Annalee Armstrong:
- Another Bidding War Breaks as Lundbeck Bids for Sleep Biotech Avadel
- Korro Suffers Cacophony of Bad News as Lead Candidate Fails, Novo Pauses RNA Deal
- Pfizer Closes Metsera Deal, Officially Ending Bidding War Drama
15. Vera Kovacevic – Science & Clinical Research Writer, Xtalks
Vera Kovacevic, PhD, writes clear, practical stories on clinical research, new technologies, AI in drug development and the future of patient-focused trials. She explains complex science in a simple way and helps readers see where clinical trials are headed.
Recent Articles by Vera Kovacevic:
- Clinical Trials by 2030: Which Emerging Technology Will Have the Biggest Impact?
- Engineering Next-Gen Radiopharmaceuticals for Precision and Safety
- Which Stage of Pharma & Biotech R&D Will Benefit Most from AI in the Next 5 Years?
Why These Reporters Lead Today’s Biotech & Pharma Conversation
Biotech and pharma are changing fast - from AI-powered drug discovery to new global competition and shifting FDA priorities. In a world where science, policy and business collide, these journalists help bring clarity and trustworthy reporting.
They explain the people, decisions and breakthroughs behind the headlines, making complex topics easy to understand and showing what they mean for patients, companies and the future of healthcare.